Structural considerations of autoantibodies

Lupus

Volumn 11, Issue 12, 2002, Pages 774-775

  Madaiol, M P ^a   Naparstek, Y ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Autoantibodies; Cytokines; Drug delivery; Immunlogic tolerance; T cells

Indexed keywords

AUTOANTIBODY; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; PEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY STRUCTURE; CELL ISOLATION; CELL SELECTION; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; AUTOANTIBODIES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE TOLERANCE; T-LYMPHOCYTES;

EID: 0036949859     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu314rp     Document Type: Conference Paper

References (2)

1. Hahn BH, Singh RR, Wong WK, Tsao BP, Bulpitt K, Ebling FM. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001; 44: 432-441.
2. Weisbart RH, Baldwin R, Huh B, Zack DJ, Nishimura R. Novel protein transfection of primary rat cortical neurons using an antibody that penetrates living cells. Journal of Immunology 2001; 164: 6020-6026.